Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Davidson

Showing results (1151-1160 of 1,190) with videos related to

Pageof 119
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 1, 1997
Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomesL P Jacobson, B C Zhang, Y R Zhu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 6, 2014
TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancerRoisin M Connolly, Jeffrey P Leal, Matthew P Goetz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2007
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical OncologyJulie Gralow, Robert F Ozols, Dean F Bajorin, et al.
British Journal of Cancer|August 14, 2014
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100B P Schneider, L Li, F Shen, et al.
Journal of Toxicology and Environmental Health. Part B, Critical Reviews|September 18, 2025
Database-calibrated toxicity values for human health assessment based on existing toxicology data for one thousand chemicalsAlison H Harrill, Shintaro Hagiwara, Chelsea A Weitekamp, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|September 22, 2025
Collaborative evaluation of in silico predictions for high throughput toxicokineticsJohn F Wambaugh, Nisha S Sipes, Gilberto Padilla Mercado, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trialEdith A Perez, Robert B Jenkins, Amylou C Dueck, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 6, 1998
Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkersT W Kensler, X He, M Otieno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2021
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline UpdateBeverly Moy, R Bryan Rumble, Steven E Come, et al.
Nature Communications|November 10, 2019
CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancerLei Nie, Yongkun Wei, Fei Zhang, et al.
Pageof 119

Showing results (1151-1160 of 1,190) with videos related to

Sort By:
Pageof 119
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 1, 1997
Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomesL P Jacobson, B C Zhang, Y R Zhu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 6, 2014
TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancerRoisin M Connolly, Jeffrey P Leal, Matthew P Goetz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2007
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical OncologyJulie Gralow, Robert F Ozols, Dean F Bajorin, et al.
British Journal of Cancer|August 14, 2014
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100B P Schneider, L Li, F Shen, et al.
Journal of Toxicology and Environmental Health. Part B, Critical Reviews|September 18, 2025
Database-calibrated toxicity values for human health assessment based on existing toxicology data for one thousand chemicalsAlison H Harrill, Shintaro Hagiwara, Chelsea A Weitekamp, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|September 22, 2025
Collaborative evaluation of in silico predictions for high throughput toxicokineticsJohn F Wambaugh, Nisha S Sipes, Gilberto Padilla Mercado, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trialEdith A Perez, Robert B Jenkins, Amylou C Dueck, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 6, 1998
Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkersT W Kensler, X He, M Otieno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2021
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline UpdateBeverly Moy, R Bryan Rumble, Steven E Come, et al.
Nature Communications|November 10, 2019
CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancerLei Nie, Yongkun Wei, Fei Zhang, et al.
Pageof 119